Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

ABSTRACT:

Purpose

The clinical value of STK11, KEAP1, and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed for this disease.

Experimental design

To develop a combinatorial biomarker strategy with increased specificity for ICB unresponsiveness in NSCLC, we performed a comprehensive analysis of 254 patients with NSCLC treated with ligand programmed death-ligand 1 (PD-L1) blockade monotherapy, including a discovery cohort of 75 patients subjected to whole-genome sequencing (WGS), and an independent validation cohort of 169 patients subjected to tumor-nor

SUBMITTER: van de Haar J 

PROVIDER: S-EPMC10982639 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature